News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

The 3 Biggest And Best Obesity-Drug Stocks To Buy In 2017



5/19/2017 6:16:24 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
Although several obesity drugs are now on the market, they haven't caught on nearly as much as biopharmaceutical companies had hoped they would. Investors looking to buy obesity-drug stocks are better off finding companies that also have other products either on the market or in development.

Eisai, Novo Nordisk, and Roche Holding Ltd. fit that description well. Each of these companies markets obesity drugs, but each also sells a broad array of other products with multiple pipeline candidates potentially on the way. Here's why Eisai, Novo Nordisk, and Roche rank as the three best obesity-drug stocks to buy in 2017.

Read at Motley Fool


comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES